Downregulation of XIAP and induction of apoptosis by the synthetic cyclin-dependent kinase inhibitor GW8510 in non-small cell lung cancer cells.

Department of Metabolism and Endocrinology, The First Affiliated Hospital, Zhejiang University, People's Republic of China.
Cancer biology & therapy (Impact Factor: 3.29). 03/2006; 5(2):165-70. DOI: 10.4161/cbt.5.2.2316
Source: PubMed

ABSTRACT Small-molecule inhibitors of cyclin-dependent kinases (CDKs) are known to induce cell cycle arrest and apoptosis in certain cancer cells. In order to evaluate the antitumor activity of one such inhibitor, GW8510, against human lung cancers, we analyzed the effects of GW8510 on six nonsmall cell lung cancer (NSCLC) cell lines (A549, H1299, H460, H226, H358 and H322) and normal human fibroblast (NHFB). We treated the cells with GW8510 at concentrations of 0-10 microM, and found that it suppressed cell growth in vitro in all the lung cancer cells but not in NHFB. Subsequent study showed that GW8510 induced apoptosis and cell cycle arrest in the A549, H1299 and H460 cells in a time- and dose-dependent manner. Western blot analysis showed that GW8510 downregulated the expression of X-linked inhibitor of apoptosis (XIAP) but had no detectable effect on the expression of Bax, Bak, or Bcl2. GW8510 also downregulated XIAP mRNA level, suggesting that downregulation of XIAP expression occurs at the transcriptional level. Moreover, ectopic XIAP expression diminished growth inhibition and apoptosis induction by GW8510. Importantly, GW8510 was not capable of inducing apoptosis of NHFB cells. These results suggest that GW8510 might provide a treatment strategy for human NSCLC and XIAP is an important target for GW8510-induced apoptosis of NSCLC cells that occurs through inhibition of XIAP mRNA transcription.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Flavaglines represent a family of plant natural products that display potent anticancer, cardioprotective, and neuroprotective activities. Novel flavagline derivatives were synthesized and examined for their cytotoxicity on a panel of human cancer cell lines, their cardioprotection against doxorubicin-induced apoptosis in cardiomyocytes, and their neuroprotection in culture models of Parkinson's disease and cisplatin-induced neurotoxicity. The structural requirements of flavaglines for cardio- and neuroprotection were for the first time unraveled and appeared to be slightly different from those for cytotoxicity on cancer cells. We provide also the first evidence that flavaglines may alleviate cisplatin-induced neurotoxicity, suggesting a prophylactic potential of these compounds to prevent this frequently encountered adverse effect of cancer chemotherapies.
    Journal of Medicinal Chemistry 10/2012; · 5.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CDKN3 (cyclin-dependent kinase inhibitor 3), a dual specificity protein phosphatase, dephosphorylates cyclin-dependent kinases (CDKs) and thus functions as a key negative regulator of cell cycle progression. Deregulation or mutations of CDNK3 have been implicated in various cancers. However, the role of CDKN3 in Bcr-Abl-mediated chronic myelogenous leukemia (CML) remains unknown. Here we found that CDKN3 acts as a tumor suppressor in Bcr-Abl-mediated leukemogenesis. Overexpression of CDKN3 sensitized the K562 leukemic cells to imanitib-induced apoptosis and dramatically inhibited K562 xenografted tumor growth in nude mouse model. Ectopic expression of CDKN3 significantly reduced the efficiency of Bcr-Abl-mediated transformation of FDCP1 cells to growth factor independence. In contrast, depletion of CDKN3 expression conferred resistance to imatinib-induced apoptosis in the leukemic cells and accelerated the growth of xenograph leukemia in mice. In addition, we found that CDKN3 mutant (CDKN3-C140S) devoid of the phosphatase activity failed to affect the K562 leukemic cell survival and xenografted tumor growth, suggesting that the phosphatase of CDKN3 was required for its tumor suppressor function. Furthermore, we observed that overexpression of CDKN3 reduced the leukemic cell survival by dephosphorylating CDK2, thereby inhibiting CDK2-dependent XIAP expression. Moreover, overexpression of CDKN3 delayed G1/S transition in K562 leukemic cells. Our results highlight the importance of CDKN3 in Bcr-Abl-mediated leukemogenesis, and provide new insights into diagnostics and therapeutics of the leukemia.
    PLoS ONE 01/2014; 9(10):e111611. · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: La protéine inhibitrice de l’apoptose, liée au chromosome X (XIAP), est un facteur important de prolifération et de progression de cancers. La réduction de l’activité XIAP conduit à l’apoptose dans le cancer anaplasique de la thyroïde (ATC), dont la mortalité dépasse 50 % des cas. Les microARN (miARN) sont de courtes séquences non codantes d’ARN qui modulent l’expression de gènes par interaction avec l’ARNm en se liant à la région 3′ non traduite (3′-UTR). Ils jouent un rôle essentiel dans la prolifération cellulaire, la migration et l’invasion. Dans cette étude, nous avons utilisé la lignée cellulaire ATC 850C et une lignée de cellules de la thyroïde humaine normale (Nthy-ori 3-1), dans le but d’identifier si un miRNA pouvait réguler l’expression de XIAP et, par conséquent, inhiber la croissance et l’invasion de la lignée ATC. Nous avons d’abord utilisé la PCR quantitative en temps réel (qPCR) pour montrer que l’expression d’ARNm de XIAP était très augmentée dans les cellules 8305C, par rapport aux cellules Nthy-ori 3-1 (×4,6 ± 0,56 ; p = 0,029). La présence de miR-618 a été retrouvée dans les cellules ATC mais en quantité moins abondante que dans les cellules 8305C (0,24 ± 0,06 ; p = 0,019). La technique de la luciférase a permis de montrer que le gène XIAP est une cible de miR-618 qui réduit son expression et sa concentration dans les cellules tumorales. Le test CCK-8 a été permis de montrer que la surexpression de miR-618 était capable d’inhiber la croissance des cellules de 8305C. Finalement, par la technique dite du « transwell » nous avons montré que miR-618 pouvait limiter l’invasion et la migration des cellules de 8305C. En conclusion, l’ensemble de ces données suggèrent que la surexpression de miR-618 en ciblant le gène XIAP est une approche thérapeutique potentielle pour réprimer la prolifération des cellules ATC.
    Annales d'Endocrinologie. 01/2014;

Full-text (2 Sources)

Available from
May 16, 2014